Available Evidence Regarding COVID-19 in the Pathogenesis of Inflammatory Bowel Disease: Role of Toll-like Receptor 7
Gastroenterology and Hepatology from Bed to Bench,
23 August 2021
Inflammatory bowel disease (IBD) pathogenesis is influenced by immune system malfunction, particularly innate immune receptors such toll-like receptors. Furthermore, due to the extreme close association between viruses and IBD incidence, it is critical to further investigation between the virus and IBD. TLRs 3, 5, and 7 are three members of TLRs family that are involved in antiviral immune responses. Finding a relationship between TLR related virus and IBD is important not only for disease pathogenesis but also for therapeutic effectiveness. Furthermore, it has been shown that influenza expresses severe in patients with IBD who use immune system inhibitors, and the influenza vaccine is less effective in these patients. In dendritic cells, TLR7 and TLR8 regulate the production of interferons (IFNs) and inflammatory mediators. COVID-19 causes the production of IL-6, which could be due to the induction of TLR pathways. TLR activation by SARS-CoV-2 causes inflammation and IL-1 production, which induces IL-6 to be produced. Understanding the TLR associated viruses’ molecular mechanism can greatly help improve the quality of life of people with IBD. Therefore, the present study aimed to review the role of TLR7, 8 and 3 in inflammatory bowel disease, their association with viral infections and to evaluate different antagonists for the treatment of IBD.
- Inflammatory bowel disease, COVID-19, Toll-like receptors, Ulcerative colitis, Crohn’s disease
2. Norouzinia M, Chaleshi V, Alizadeh AHM, Zali MRJG, bench hfbt. Biomarkers in inflammatory bowel diseases: insight into diagnosis, prognosis and treatment. 2017;10(3):155.
3. Bonen DK, Cho JHJG. The genetics of inflammatory bowel disease. 2003;124(2):521-36.
4. Hensel KO, Boland V, Postberg J, Zilbauer M, Heuschkel R, Vogel S, Gödde D, Wirth S, Jenke ACJSr. Differential expression of mucosal trefoil factors and mucins in pediatric inflammatory bowel diseases. 2014;4(1):1-5.
5. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida HJTAjocn. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. 2010;91(5):1255-60.
6. Boltin D, Gingold-Belfer R, Kimchi NA, Ben-Bassat O, Niv Y, Birkenfeld SJIbd. Utilization of Influenza Immunization in Adults with Crohn's Disease—A Longitudinal, Population-Based Study. 2014;20(2):240-5.
7. Jester BJ, Uyeki TM, Jernigan DBJAjoph. Fifty years of influenza A (H3N2) following the pandemic of 1968. 2020;110(5):669-76.
8. Magro F, Abreu C, Rahier J-FJUEgj. The daily impact of COVID-19 in gastroenterology. 2020;8(5):520-7.
9. Di Gennaro F, Pizzol D, Marotta C, Antunes M, Racalbuto V, Veronese N, Smith LJIjoer, health p. Coronavirus diseases (COVID-19) current status and future perspectives: a narrative review. 2020;17(8):2690.
10. Sheehan D, Shanahan FJGC. The gut microbiota in inflammatory bowel disease. 2017;46(1):143-54.
11. Manichanh C, Borruel N, Casellas F, Guarner FJNrG, hepatology. The gut microbiota in IBD. 2012;9(10):599.
12. Cario EJIbd. Toll-like receptors in inflammatory bowel diseases: a decade later. 2010;16(9):1583-97.
13. Kumar M, Carmichael GGJM, Reviews MB. Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes. 1998;62(4):1415.
14. Mogensen THJCmr. Pathogen recognition and inflammatory signaling in innate immune defenses. 2009;22(2):240-73.
15. Dwyer AL, Cummings ALJCJoC, Psychotherapy. Stress, self-efficacy, social support, and coping strategies in university students. 2001;35(3).
16. e Sousa CR, editor Toll-like receptors and dendritic cells: for whom the bug tolls. Seminars in immunology; 2004: Elsevier.
17. Arpaia N, Barton GMJCoiv. Toll-like receptors: key players in antiviral immunity. 2011;1(6):447-54.
18. Xagorari A, Chlichlia KJTomj. Toll-like receptors and viruses: induction of innate antiviral immune responses. 2008;2:49.
19. Ma Z, Liu J, Wu W, Zhang E, Zhang X, Li Q, Zelinskyy G, Buer J, Dittmer U, Kirschning CJJC, immunology m. The IL-1R/TLR signaling pathway is essential for efficient CD8+ T-cell responses against hepatitis B virus in the hydrodynamic injection mouse model. 2017;14(12):997-1008.
20. Zhang H, Gregorio JD, Iwahori T, Zhang X, Choi O, Tolentino LL, Prestwood T, Carmi Y, Engleman EGJPotNAoS. A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes. 2017;114(8):1988-93.
21. Lee S-M, Joo Y-D, Seo S-KJIn. Expression and function of TLR2 on CD4 versus CD8 T cells. 2009;9(4):127.
22. Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FYJPotNAoS. TLR2 is expressed on activated T cells as a costimulatory receptor. 2004;101(9):3029-34.
23. Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto MRJG. TLR7 agonist increases responses of hepatitis B virus–specific T cells and natural killer cells in patients with chronic hepatitis B treated with nucleos (t) ide analogues. 2018;154(6):1764-77. e7.
24. Li L, Barry V, Daffis S, Niu C, Huntzicker E, French DM, Mikaelian I, Lanford RE, Delaney IV WE, Fletcher SPJJoh. Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells. 2018;68(5):912-21.
25. de Franchis RJJoh. Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. 2010;53(4):762-8.
26. Song Y, Zhuang Y, Zhai S, Huang D, Zhang Y, Kang W, Li X, Liu Q, Yu Q, Sun YJAr, retroviruses h. Increased Expression of TLR7 in CD8+ T Cells Leads to TLR7-Mediated Activation and Accessory Cell-Dependent IFN-γ Production in HIV Type 1 Infection. 2009;25(12):1287-95.
27. Salerno F, Guislain A, Cansever D, Wolkers MCJTJoI. TLR-mediated innate production of IFN-γ by CD8+ T cells is independent of glycolysis. 2016;196(9):3695-705.
28. Geng D, Zheng L, Srivastava R, Asprodites N, Velasco-Gonzalez C, Davila EJB, The Journal of the American Society of Hematology. When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function. 2010;116(18):3494-504.
29. Petes C, Odoardi N, Gee KJFii. The toll for trafficking: toll-like receptor 7 delivery to the endosome. 2017;8:1075.
30. Li Q, Yan Y, Liu J, Huang X, Zhang X, Kirschning C, Xu HC, Lang PA, Dittmer U, Zhang EJFii. Toll-like receptor 7 activation enhances CD8+ T cell effector functions by promoting cellular glycolysis. 2019;10:2191.
31. Acuto O, Michel FJNRI. CD28-mediated co-stimulation: a quantitative support for TCR signalling. 2003;3(12):939-51.
32. Haring JS, Badovinac VP, Harty JTJI. Inflaming the CD8+ T cell response. 2006;25(1):19-29.
33. Carracedo A, Cantley LC, Pandolfi PPJNrC. Cancer metabolism: fatty acid oxidation in the limelight. 2013;13(4):227-32.
34. Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JAJI. CD28 costimulation: from mechanism to therapy. 2016;44(5):973-88.
35. Caron G, Duluc D, Frémaux I, Jeannin P, David C, Gascan H, Delneste YJTJoI. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-γ production by memory CD4+ T cells. 2005;175(3):1551-7.
36. Rubtsova K, Rubtsov AV, Halemano K, Li SX, Kappler JW, Santiago ML, Marrack PJPO. T cell production of IFNγ in response to TLR7/IL-12 stimulates optimal B cell responses to viruses. 2016;11(11):e0166322.
37. Sainathan SK, Bishnupuri KS, Aden K, Luo Q, Houchen CW, Anant S, Dieckgraefe BKJIbd. Toll-like receptor-7 ligand Imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis. 2012;18(5):955-67.
38. Kiyohara H, Sujino T, Teratani T, Miyamoto K, Arai MM, Nomura E, Harada Y, Aoki R, Koda Y, Mikami YJC, gastroenterology m, hepatology. Toll-Like Receptor 7 Agonist–Induced Dermatitis Causes Severe Dextran Sulfate Sodium Colitis by Altering the Gut Microbiome and Immune Cells. 2019;7(1):135-56.
39. Ebrahimi MM, Shahsavandi S, Shayan PJVi. TIR-TLR7 as a Molecular Adjuvant: Simultaneous Enhancing Humoral and Cell-Mediated Immune Responses Against Inactivated Infectious Bursal Disease Virus. 2019;32(6):252-7.
40. Karlsson L, Sun S, Rao NL, Venable J, Thurmond RJI, Targets A-D. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. 2007;6(4):223-35.
41. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JIJs. Host-bacterial mutualism in the human intestine. 2005;307(5717):1915-20.
42. Maronek M, Link R, Ambro L, Gardlik RJC. Phages and their role in gastrointestinal disease: Focus on inflammatory bowel disease. 2020;9(4):1013.
43. Iliev ID, Cadwell KJG. Effects of Intestinal Fungi and Viruses on Immune Responses and Inflammatory Bowel Diseases. 2020.
44. Tarris G, de Rougemont A, Charkaoui M, Michiels C, Martin L, Belliot G. Enteric Viruses and Inflammatory Bowel Disease. Viruses 2021, 13, 104. s Note: MDPI stays neu-tral with regard to jurisdictional clai-ms in …; 2021.
45. de Rivero Vaccari JC, Dietrich WD, Keane RW, de Rivero Vaccari JPJFii. The Inflammasome in Times of COVID-19. 2020;11:2474.
46. Lester SN, Li KJJomb. Toll-like receptors in antiviral innate immunity. 2014;426(6):1246-64.
47. Carty M, Bowie AGJC, Immunology E. Recent insights into the role of Toll‐like receptors in viral infection. 2010;161(3):397-406.
48. Saghazadeh A, Rezaei NJEoott. Implications of Toll-like receptors in Ebola infection. 2017;21(4):415-25.
49. Florindo HF, Kleiner R, Vaskovich-Koubi D, Acúrcio RC, Carreira B, Yeini E, Tiram G, Liubomirski Y, Satchi-Fainaro RJNn. Immune-mediated approaches against COVID-19. 2020;15(8):630-45.
50. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R. A novel coronavirus from patients with pneumonia in China, 2019. New England journal of medicine. 2020.
51. Chen Y, Liu Q, Guo DJJomv. Emerging coronaviruses: genome structure, replication, and pathogenesis. 2020;92(4):418-23.
52. Paybast S, Emami A, Koosha M, Baghalha FJANT. Novel coronavirus disease (COVID-19) and central nervous system complications: what neurologist need to know. 2020;29(1):24-31.
53. Kimura A, Kishimoto TJEjoi. IL‐6: regulator of Treg/Th17 balance. 2010;40(7):1830-5.
54. Zhang Q, Li B, Huang S, Nomura H, Tanaka H, Adachi CJNP. Efficient blue organic light-emitting diodes employing thermally activated delayed fluorescence. 2014;8(4):326-32.
55. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJJTl. COVID-19: consider cytokine storm syndromes and immunosuppression. 2020;395(10229):1033-4.
56. McElvaney OJ, McEvoy NL, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM, Ní Choileáin O, Clarke J, O’Connor E, Hogan GJAjor, medicine cc. Characterization of the inflammatory response to severe COVID-19 illness. 2020;202(6):812-21.
57. Fehniger TA, Cooper MA, Caligiuri MAJC, reviews gf. Interleukin-2 and interleukin-15: immunotherapy for cancer. 2002;13(2):169-83.
58. Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, Sinclaire BA, Bednarz U, Marafelias M, Hansen EJTLR. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. 2020;2(10):e603-e12.
59. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, Wang L, Zhou N, Petty LA, Baang JH, Dillman NO. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clinical Infectious Diseases. 2020.
60. Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences. 2020;117(20):10970-5.
61. Yousif AS, Ronsard L, Shah P, Omatsu T, Sangesland M, Moreno TB, Lam EC, Vrbanac VD, Balazs AB, Reinecker H-C. The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells. Immunity. 2021;54(2):235-46. e5.
62. Weidinger C, Hegazy AN, Glauben R, Siegmund B. COVID-19—from mucosal immunology to IBD patients. Mucosal Immunology. 2021:1-8.
63. Tabary M, Khanmohammadi S, Araghi F, Dadkhahfar S, Tavangar SM. Pathologic features of COVID-19: A concise review. Pathology-Research Practice. 2020:153097.
64. Jabbari P, Jabbari F, Ebrahimi S, Rezaei NJDm, preparedness ph. COVID-19: a chimera of two pandemics. 2020;14(3):e38-e9.
65. Sahu KK, Siddiqui AD, Cerny J. Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside. Laboratory medicine. 2021;52(1):24-35.
66. Thwaini MH, Al-Mudhafar RH, Hadi NR. Effects of Resatorvid on brain ischemic reperfusion injury in rats. European Journal of Molecular Clinical Medicine. 2021;7(1):4395-405.
67. Fitzgerald KA, Kagan JCJC. Toll-like receptors and the control of immunity. 2020;180(6):1044-66.
68. Angelopoulou A, Alexandris N, Konstantinou E, Mesiakaris K, Zanidis C, Farsalinos K, Poulas KJER. Imiquimod-A toll like receptor 7 agonist-Is an ideal option for management of COVID 19. 2020;188:109858.
69. Moreno-Eutimio MA, López-Macías C, Pastelin-Palacios RJM, infection. Bioinformatic analysis and identification of single-stranded RNA sequences recognized by TLR7/8 in the SARS-CoV-2, SARS-CoV, and MERS-CoV genomes. 2020;22(4-5):226-9.
70. de Groot NG, Bontrop RE. COVID-19 pandemic: is a gender-defined dosage effect responsible for the high mortality rate among males? : Springer; 2020.
71. Patra R, Chandra Das N, Mukherjee S. Targeting human TLRs to combat COVID‐19: A solution? Journal of medical virology. 2021;93(2):615-7.
72. Totura AL, Whitmore A, Agnihothram S, Schäfer A, Katze MG, Heise MT, Baric RSJM. Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. 2015;6(3):e00638-15.
73. Onofrio L, Caraglia M, Facchini G, Margherita V, Placido SD, Buonerba C. Toll-like receptors and COVID-19: a two-faced story with an exciting ending. Future Science; 2020.
74. Sohn KM, Lee S-G, Kim HJ, Cheon S, Jeong H, Lee J, Kim IS, Silwal P, Kim YJ, Paik S. COVID-19 patients upregulate toll-like receptor 4-mediated inflammatory signaling that mimics bacterial sepsis. Journal of Korean medical science. 2020;35(38).
- Abstract Viewed: 0 times